(Q37929546)

25 August 2017

1 reference

title

Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia (English)

1 reference

25 August 2017

1 reference

1 reference

0 references

E Lengfelder

1

1 reference

25 August 2017

W-K Hofmann

series ordinal

2

1 reference

25 August 2017

D Nowak

series ordinal

3

1 reference

25 August 2017

publication date

9 September 2011

1 reference

25 August 2017

1 reference

25 August 2017

volume

26

1 reference

25 August 2017

issue

3

1 reference

25 August 2017

page(s)

433-442

1 reference

Proposals for the Classification of the Acute Leukaemias French-American-British (FAB) Co-operative Group

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Rearrangements of the retinoic acid receptor alpha and promyelocytic leukemia zinc finger genes resulting from t(11;17)(q23;q21) in a patient with acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Treatment concepts of acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Hematopoietic stem cell transplantation for adults with acute promyelocytic leukemia in the ATRA era: a survey of the European Cooperative Group for Blood and Marrow Transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Revisiting the differentiation paradigm in acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Arsenic inhibition of telomerase transcription leads to genetic instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Arsenic-induced APL differentiation in cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Determinants of cerebrospinal fluid arsenic concentration in patients with acute promyelocytic leukemia on oral arsenic trioxide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Combined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Arsenic trioxide and ascorbic acid: synergy with potential implications for the treatment of acute myeloid leukaemia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Arsenic trioxide (trisenox) therapy for acute promyelocytic leukemia in the setting of hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Arsenic trioxide in comparison with chemotherapy and bone marrow transplantation for the treatment of relapsed acute promyelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Prolonged molecular remission after arsenic trioxide and all-trans retinoic acid for acute promyelocytic leukemia relapsed after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Extramedullary involvement at relapse in acute promyelocytic leukemia patients treated or not with all-trans retinoic acid: a report by the Gruppo Italiano Malattie Ematologiche dell'Adulto

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

CNS relapse in acute promyeloctyic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

The "Retinoic Acid Syndrome" in Acute Promyelocytic Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Fusion of retinoic acid receptor alpha to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

The seventh pathogenic fusion gene FIP1L1-RARA was isolated from a t(4;17)-positive acute promyelocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Treatment of acute promyelocytic leukemia in the very elderly: case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Hematopoietic stem cell transplantation for acute promyelocytic leukemia in second or third complete remission: a retrospective analysis in the Nagoya Blood and Marrow Transplantation Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation. APL Study Group. Acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

7 January 2021

Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

7 January 2021

Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

7 January 2021

A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

7 January 2021

Elemental arsenic entered the cerebrospinal fluid during oral arsenic trioxide treatment of meningeal relapse of acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

7 January 2021

Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

7 January 2021

Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

7 January 2021

Efficacy of prolonged therapy with combined arsenic trioxide and ATRA for relapse of acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

7 January 2021

Recurrent extramedullary relapse of acute promyelocytic leukemia after allogeneic stem cell transplantation: successful treatment by arsenic trioxide in combination with local radiotherapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

7 January 2021

Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

7 January 2021

The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic-like leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

7 January 2021

Relapsed APL patient with variant NPM-RARalpha fusion responded to arsenic trioxide-based therapy and achieved long-term survival

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

7 January 2021

Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

7 January 2021

Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia: results in patients treated in second molecular remission or with molecularly persistent disease

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.245

7 January 2021

Identifiers

DOI

10.1038/LEU.2011.245

1 reference

Dimensions Publication ID

25 August 2017

1049789396

0 references

1 reference